Diabetes Care, Vol 23, Issue 6 838-844, Copyright © 2000 by American Diabetes Association

ARTICLES

High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. The Belgian Diabetes Registry

K Decochez, J Tits, JL Coolens, L Van Gaal, G Krzentowski, F Winnock, E Anckaert, I Weets, DG Pipeleers and FK Gorus
Diabetes Research Center, Academic Hospital, Vrije University Brussel, Brussels, Belgium.

OBJECTIVE: To study the presence and levels of GAD65 antibodies (GADA), IA-2 antibodies (IA-2-A), and islet cell antibodies (ICA) during the first years after clinical onset of type 1 diabetes in relation to age at diagnosis. RESEARCH DESIGN AND METHODS: Type 1 diabetic patients (n = 194) <40 years of age were consecutively recruited at the time of diagnosis by the Belgian Diabetes Registry and followed during the first 4 years of insulin treatment. ICA were determined by indirect immunofluorescence assay and IA-2-A, GADA, and insulin autoantibodies by a radioligand assay. RESULTS: Overall, 94% of initially antibody-positive patients (n = 180) remained positive for at least 1 antibody type 4 years after diagnosis. In the case of diagnosis after 7 years of age, GADA, IA-2-A, and ICA persisted in 91, 88, and 71%, respectively, of the initially antibody-positive patients. Antibody persistence was lower in those diagnosed at <7 years of age, amounting to 60% for GADA, 71% for IA-2-A, and 39% for ICA. In 57% of the initially antibody-positive patients, at least 1 type of autoantibody reached peak values after diagnosis. This occurred more frequently for clinical onset after 7 years of age and more often for GADA (49%) than for IA-2-A (29%) or ICA (19%). Of the patients, 24% that were negative for GADA at onset became GADA-positive during the following 4 years. Among the 7% initially antibody-negative patients, 2 of 14 subjects developed antibodies after clinical onset. CONCLUSIONS: In particular, for diagnosis after 7 years of age, islet cell-specific autoantibodies generally persist for many years after diagnosis. There is also a high frequency of increasing antibody levels and of conversion to antibody positivity in the first 4 years after diagnosis and start of insulin treatment. Thus, determination of antibodies at diagnosis can underestimate the number of cases with autoimmune type 1 diabetes, in particular with assays of lower sensitivity. The divergent temporal patterns of ICA, GADA, and IA-2-A suggest that the ICA test recognizes other antibody specificities besides GADA and IA-2-A and reflects other autoimmune processes; it also indicates that GADA assays have a higher diagnostic sensitivity in the period after clinical onset.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. Maruyama, S. Oak, A. Shimada, and C. S. Hampe GAD65 Autoantibody Responses in Japanese Latent Autoimmune Diabetes in Adult Patients Diabetes Care, August 1, 2008; 31(8): 1602 - 1607. [Abstract] [Full Text] [PDF]

				A W van Deutekom, M T Nurmohamed, M J L Peters, I C van Eijk, B A C Dijkmans, D Hamann, R J Heine, and S Simsek Methotrexate and its effect on the anti-GAD titre in two patients with rheumatoid arthritis and diabetes mellitus Ann Rheum Dis, July 1, 2008; 67(7): 1051 - 1052. [Full Text] [PDF]

				A. Balasubramanyam, R. Nalini, C. S. Hampe, and M. Maldonado Syndromes of Ketosis-Prone Diabetes Mellitus Endocr. Rev., May 1, 2008; 29(3): 292 - 302. [Abstract] [Full Text] [PDF]

				S. Oak, L. K. Gilliam, M. Landin-Olsson, C. Torn, I. Kockum, C. R. Pennington, M. J. Rowley, M. R. Christie, J. P. Banga, and C. S. Hampe The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes PNAS, April 8, 2008; 105(14): 5471 - 5476. [Abstract] [Full Text] [PDF]

				K. M. Gillespie Type 1 diabetes: pathogenesis and prevention. Can. Med. Assoc. J., July 18, 2006; 175(2): 165 - 170. [Abstract] [Full Text] [PDF]

				B. Keymeulen, E. Vandemeulebroucke, A. G. Ziegler, C. Mathieu, L. Kaufman, G. Hale, F. Gorus, M. Goldman, M. Walter, S. Candon, et al. Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes N. Engl. J. Med., June 23, 2005; 352(25): 2598 - 2608. [Abstract] [Full Text] [PDF]

				G. Biesenbach, M. Auinger, M. Clodi, F. Prischl, R. Kramar, and Diabetic Nephropathy Study Group of the Austrian S Prevalence of LADA and frequency of GAD antibodies in diabetic patients with end-stage renal disease and dialysis treatment in Austria Nephrol. Dial. Transplant., March 1, 2005; 20(3): 559 - 565. [Abstract] [Full Text] [PDF]

				S. Tanaka, T. Endo, K. Aida, H. Shimura, N. Yokomori, M. Kaneshige, F. Furuya, S. Amemiya, M. Mochizuki, K. Nakanishi, et al. Distinct Diagnostic Criteria of Fulminant Type 1 Diabetes Based on Serum C-Peptide Response and HbA1c Levels at Onset Diabetes Care, August 1, 2004; 27(8): 1936 - 1941. [Abstract] [Full Text] [PDF]

				B. F. Hoyer, K. Moser, A. E. Hauser, A. Peddinghaus, C. Voigt, D. Eilat, A. Radbruch, F. Hiepe, and R. A. Manz Short-lived Plasmablasts and Long-lived Plasma Cells Contribute to Chronic Humoral Autoimmunity in NZB/W Mice J. Exp. Med., June 7, 2004; 199(11): 1577 - 1584. [Abstract] [Full Text] [PDF]

				J. P. Palmer, G. A. Fleming, C. J. Greenbaum, K. C. Herold, L. D. Jansa, H. Kolb, J. M. Lachin, K. S. Polonsky, P. Pozzilli, J. S. Skyler, et al. C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve {beta}-Cell Function: Report of an ADA Workshop, 21-22 October 2001 Diabetes, January 1, 2004; 53(1): 250 - 264. [Abstract] [Full Text] [PDF]

				I. Weets, V. Siraux, J.-C. Daubresse, I. H. De Leeuw, F. Fery, B. Keymeulen, G. Krzentowski, M. Letiexhe, C. Mathieu, F. Nobels, et al. Relation between Disease Phenotype and HLA-DQ Genotype in Diabetic Patients Diagnosed in Early Adulthood J. Clin. Endocrinol. Metab., June 1, 2002; 87(6): 2597 - 2605. [Abstract] [Full Text] [PDF]

				H. Borg, A. Gottsater, P. Fernlund, and G. Sundkvist A 12-Year Prospective Study of the Relationship Between Islet Antibodies and {beta}-Cell Function At and After the Diagnosis in Patients With Adult-Onset Diabetes Diabetes, June 1, 2002; 51(6): 1754 - 1762. [Abstract] [Full Text] [PDF]

				F. Winnock, M. R. Christie, M. R. Batstra, H.-J. Aanstoot, I. Weets, K. Decochez, P. Jopart, D. Nicolaij, and F. K. Gorus Autoantibodies to a 38-kDa Glycosylated Islet Cell Membrane-Associated Antigen in (Pre)type 1 Diabetes: Association with IA-2 and islet cell autoantibodies Diabetes Care, July 1, 2001; 24(7): 1181 - 1186. [Abstract] [Full Text] [PDF]